Ariad’s brigatinib scores 15.6 month PFS rate; Neurimmune backs ALS spinout
Ariad Pharmaceuticals is reporting that its ALK inhibitor brigatinib scored a 55% objective response rate in among patients taking 180 mg. In this same arm the PFS rate was a median 15.6 months. “These updated ALTA trial data show that with additional follow-up, median progression-free survival from brigatinib given post-crizotinib is now 15.6 months, and that this is the same whether assessed by the investigators or an independent review committee,” said D. Ross Camidge, MD, PhD., director of thoracic oncology at the University of Colorado.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.